Numinus Wellness Inc. (NUMIF)
| Previous Close | 0.0522 |
| Open | 0.0525 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0513 - 0.0530 |
| 52 Week Range | 0.0500 - 0.2010 |
| Volume | |
| Avg. Volume | 288,614 |
| Market Cap | 16.605M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | Jul 15, 2024 - Jul 19, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.25 |
- Baystreet
Stocks in play: Numinus Wellness Inc.
Announced that its research site, Cedar Clinical Research, has been chosen as one of multiple sites ...
CNW GroupCedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, is proud to announce that its research site, Cedar Clinical Research ("CCR"), has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD").
PR NewswireNuminus Wellness Provides Corporate Update
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, provides an update following unauthorized disclosure in an online newspaper which has come to its attention.
